Form 4: Provectus Biopharmaceuticals CEO Converts Debt to Preferred Stock

Provectus Biopharmaceuticals CEO, Edward Pershing, converted a promissory note into preferred stock, increasing his holdings in the company.

Summary

• Edward Pershing, CEO of Provectus Biopharmaceuticals, converted an 8% unsecured convertible promissory note into 18,880 shares of Series D-1 Convertible Preferred Stock on November 29, 2024.
• The conversion was triggered automatically twelve months after the issue date of the note, which was part of the company's 2022 financing.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock.
• The Series D-1 Preferred Stock will automatically convert into common stock on June 20, 2026, unless converted earlier.
• Following the conversion, Pershing directly owns 1,710,584 shares of common stock and 18,880 shares of Series D-1 Convertible Preferred Stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction, with no significant positive or negative implications. The conversion was expected and does not indicate a major shift in the company's financial health or outlook.

Positives

• The conversion of the promissory note into preferred stock simplifies the company's capital structure.
• The CEO's increased stake in the company through preferred stock could signal confidence in the company's future.

Risks

• The conversion of preferred stock to common stock on June 20, 2026, could potentially dilute existing shareholders if not converted earlier.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into common stock on June 20, 2026, unless converted earlier.

Industry Context

This transaction is a routine filing related to changes in beneficial ownership by a company insider and is not indicative of broader industry trends.

Comparison to Industry Standards

• SEC Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders.
• The conversion of debt to equity is a common financial transaction, especially for smaller companies.

Stakeholder Impact

• The conversion of preferred stock to common stock on June 20, 2026, could potentially dilute existing shareholders.

Key Dates

Keywords

Provectus Biopharmaceuticals, Edward Pershing, Series D-1 Convertible Preferred Stock, Promissory Note, SEC Form 4, Beneficial Ownership, Convertible Securities, CEO, PVCT